drugset / Trial / NCT00271323
Safety Study of Docetaxel/Cisplatin Induction Therapy Followed by Concurrent Chemoradiotherapy or Concurrent Chemoradiotherapy Followed by Consolidation Docetaxel/Cisplatin in NSCLC Patients
RandomizedParallel-groupOpen-labelTreatment
Summary
* Primary : To determine the safety profile of each treatment group. * Secondary : To determine efficacy in term of overall response, disease free survival and survival at 1 and 2 years.
Timeline
- Start
- 2005-05
- Primary completion
- 2007-02
- Completion
- 2007-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cisplatin | Other / unclassified | 20 mg/m2 | Intravenous |
| Subject | Cisplatin | Other / unclassified | 40 mg/m2 | Intravenous |
| Subject | Docetaxel | Small molecule | 20 mg/m2 | Intravenous |
| Subject | Docetaxel | Small molecule | 75 mg/m2 | Intravenous |